84.03
前日終値:
$83.89
開ける:
$83.955
24時間の取引高:
2.08M
Relative Volume:
0.58
時価総額:
$32.95B
収益:
$4.15B
当期純損益:
$535.20M
株価収益率:
62.71
EPS:
1.34
ネットキャッシュフロー:
$575.20M
1週間 パフォーマンス:
-1.52%
1か月 パフォーマンス:
+5.04%
6か月 パフォーマンス:
-2.65%
1年 パフォーマンス:
-24.74%
Dexcom Inc Stock (DXCM) Company Profile
DXCM を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
DXCM
Dexcom Inc
|
84.03 | 33.46B | 4.15B | 535.20M | 575.20M | 1.34 |
![]()
ABT
Abbott Laboratories
|
124.42 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
387.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
89.70 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
76.56 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-16 | 開始されました | Truist | Buy |
2025-05-30 | 開始されました | Goldman | Buy |
2025-04-10 | 開始されました | Mizuho | Outperform |
2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
2023-03-29 | 開始されました | UBS | Buy |
2023-01-26 | 開始されました | Wolfe Research | Outperform |
2022-10-18 | 開始されました | Barclays | Equal Weight |
2022-10-12 | 開始されました | Jefferies | Buy |
2022-07-15 | 開始されました | Bernstein | Outperform |
2022-03-02 | 再開されました | BofA Securities | Buy |
2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
2021-07-21 | 再開されました | Cowen | Outperform |
2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2021-05-25 | 開始されました | Barclays | Overweight |
2021-04-15 | 開始されました | Atlantic Equities | Overweight |
2021-01-06 | アップグレード | UBS | Neutral → Buy |
2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
2020-03-05 | 開始されました | Citigroup | Buy |
2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
2019-10-23 | 開始されました | Stifel | Buy |
2018-11-28 | 開始されました | UBS | Neutral |
2018-10-19 | アップグレード | Goldman | Sell → Neutral |
2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
2018-05-11 | 開始されました | BofA/Merrill | Buy |
2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
2018-04-04 | 開始されました | Goldman | Sell |
2018-04-04 | 開始されました | Guggenheim | Neutral |
2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
What drives DexCom Inc. stock priceConsistent high-performance stocks - Autocar Professional
What analysts say about DexCom Inc. stockMassive portfolio appreciation - Autocar Professional
DexCom Inc. Stock Analysis and ForecastUnmatched profit potential - Autocar Professional
DexCom: Delivering Consistent Growth (NASDAQ:DXCM) - Seeking Alpha
Still Too Pricey? Dexcom’s Double-Digit Growth May Not Be Enough (DXCM) - Seeking Alpha
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years - AOL.com
Is DexCom Inc. a good long term investmentUnrivaled growth potential - jammulinksnews.com
Dexcom recalls 19 models of glucose monitoring receivers - Modern Healthcare
Dexcom’s Recall of Certain CGM Receivers is Class I - Medical Product Outsourcing
Foletta sells Dexcom (DXCM) shares worth $234,216 - Investing.com Australia
Foletta sells Dexcom (DXCM) shares worth $234,216 By Investing.com - Investing.com Canada
FDA updates recall of certain Dexcom CGM speakers (DXCM) - Seeking Alpha
Assessing the Impact of Dexcom's Critical Device Recall on Its Market Position and Investor Sentiment - AInvest
Dexcom recalls glucose monitor receivers due to alert failure risk - Investing.com
Dexcom recalls glucose monitor receivers due to alert failure risk By Investing.com - Investing.com UK
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews - The News-Gazette
DexCom (DXCM) Target Price Raised by Mizuho Analyst | DXCM Stock News - GuruFocus
Analyst recommendations: Airbnb, Dexcom, Gitlab, AMD, Citigroup… - MarketScreener
Morgan Stanley Adjusts DexCom Price Target to $89 From $82, Maintains Equal Weight Rating - MarketScreener
Beyond The Numbers: 8 Analysts Discuss DexCom Stock - Benzinga
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
When Should You Buy DexCom, Inc. (NASDAQ:DXCM)? - 富途牛牛
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Benzinga
DexCom, Inc. (DXCM) Stock Analysis: Evaluating a 18.25% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Ravens’ Mark Andrews leads first Dexcom U Signing Day Camp, inspiring young athletes with diabetes - WMAR 2 News Baltimore
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock. - Barron's
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day - Investegate
What You Need to Know Ahead of DexCom’s Earnings Release - MSN
What You Need To Know Ahead Of DexCom’s Earnings Release - Barchart.com
Oppenheimer Reaffirms DexCom Buy Rating Amid HHS Wearables Push - MSN
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? - Nasdaq
3 Reasons Growth Investors Will Love DexCom (DXCM) - Yahoo Finance
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time. - BioSpace
DexCom (DXCM) Leads Healthcare Sector Gains - GuruFocus
15 Best Fundamental Stocks to Buy According to Hedge Funds - Insider Monkey
Here's Why DexCom (DXCM) is a Strong Momentum Stock - Yahoo Finance
DexCom’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Yahoo Finance
Can DexCom’s Stock Keep Rising? - timothysykes.com
Abbott stock DexCom stock gain on RFK Jr. comments (DXCM) - Seeking Alpha
Dexcom shares U.S. report on CGM benefits for type 2 diabetes - MassDevice
DXCM's Access Gains and Operational Strength Offset Margin Pressures - TradingView
Dexcom EVP Brown sells $41k in shares - Investing.com
Diabetics at Risk: FDA Issues Highest-Level Recall on 2M Dexcom Devices Over 'Deadly Fault' - inkl
Global Artificial Pancreas Devices Market is Gearing Up for Outstanding Expansion at a CAGR of ~16% by 2032 | DelveInsight - GlobeNewswire Inc.
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):